NCT02667327终止3 期
A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle Controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 124
- 试验地点
- 29
- 主要终点
- Incidence of complete wound closure at Week 12 based on investigator assessment
研究概览
简要总结
The purpose of this study is to determine whether Granexin gel is safe and effective in the treatment of diabetic foot ulcers.
详细描述
DFU patients will undergo a one week screening period and those with changes in ulcer size of less than 30% will be eligible for randomization providing all other criteria are met. Participants enrolled in the study will receive treatment based on randomization into 1 of 3 treatment arms for up to 12 weeks. The participants will have an additional 12 week follow-up period beyond the treatment period to assess durability of wound closure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Both male and female participants may participate in the study.
- •To be eligible for entry into this study, a patient must meet all of the following Inclusion criteria:
- •Age 18 years or older
- •Established diagnosis of diabetes mellitus (type I or II)
- •Glycosylated hemoglobin (HbA1c) value < 12.0% at the screening visit
- •Diagnosis of neuropathic foot ulcer by 10g monofilament test, tuning fork (128 Hz), or cotton wisp
- •Designated foot ulcer meets the following criteria at both the screening and baseline visits:
- •Present for at least 4 weeks
- •Full-thickness cutaneous ulcer below the ankle surface
- •University of Texas grade A1
- •Wound area (after debridement) 1 to 40.0 cm2
- •Viable, granulating wound (investigator discretion)
- •Ankle brachial index ≤ 0.7 at both the screening and baseline visits. If the ABI is >1.30, one of the following confirmatory tests must be performed for the patient to be considered eligible:
- •Does Not have a monophonic or biphasic flow (with the loss of reverse flow) in the artery of the foot with the target ulcer via doppler waveform analysis of the dorsalis pedis and posterior tibial arteries, as determined by standard practices of the investigator and the site.
- •Transcutaneous oxygen pressure (TcPO2) at the foot >40 mmHg
- •Additionally, patients must meet all other protocol-defined eligibility criteria.
- •Signed informed consent
- •Female patients of childbearing potential must have a negative pregnancy test at screening and must agree to use hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence throughout until 2 weeks after the last administration of investigational product. Male patients must also agree to use contraception such as a condom.
排除标准
- •Patients will not be eligible for enrollment in the study if they meet any of the exclusion criterial listed below:
- •Change (decrease or increase) in size of the designated target ulcer by ≥ 30% during the 7-day screening period
- •Cannot tolerate the off-loading methods or cannot comply with study related procedures
- •Has an ulcer that meets any of the following criteria:
- •Shows signs of severe clinical infection, defined as pus oozing from the ulcer site
- •Requires surgical debridement
- •Is positive for β-hemolytic streptococci upon culture performed prior to screening debridement procedure
- •Has > 50% slough, significant necrotic tissue, bone, tendon, or capsule exposure
- •Is highly exuding (i.e., requires daily change of dressing)
- •Requires total contact cast
- •Ankle brachial pressure index < 0.7
- •Has a local or systemic infection or local lymphangitis ≥ 0.5 cm
- •Has any 1 of the following (only 1 of the 2 tests is required):
- •A monophasic or biphasic flow (with loss of reverse flow) in the artery of the foot with the target ulcer via doppler waveform analysis of the dorsalis pedis and posterior tibial arteries
- •Transcutaneous oxygen pressure (TcPO2) at the foot <40 mgHg
- •Presence of active malignant or benign tumor of any kind, (with the exception to nonmelanoma skin cancer as per investigator's discretion)
- •Congestive heart failure (New York Heart Association class II-IV)
- •Coronary heart disease with ST segment elevation myocardial infarction or coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the last 6 months
- •Active osteomyelitis of the foot with the target ulcer detected by x-ray, CT scan, or MRI
- •Active connective tissue disease
- •Acute or chronic Charcot's neuro-arthropathy as determined by clinical and/or radiographic examination
- •Active treatment with systemic corticosteroids or topical corticosteroids (for treatment of the target ulcer or any area of the foot). This does not include inhaled corticosteroids used for conditions other than treating the target ulcer or any area of the foot. Wash out period for systemic corticosteroids is 14 days for inclusion in this study. Wash out period for topical corticosteroids (for treatment of the target ulcer or any area of the foot) is 14 days for inclusion in the study)
- •Active treatment with systemic antibiotics (wash out period for systemic antibiotics is 7 days for the inclusion in the study)
- •Previous or current radiation therapy to the distal lower extremity or likelihood to receive this therapy during study participation
- •Pregnant or nursing mothers
- •Uncontrolled anemia (hemoglobin < 10 g/dL in females and < 12 g/dL in males)
- •Estimated glomerular filtration rate < 25 mL/min
- •Poor nutritional status, defined as an albumin < 25 g/L (< 2,500 mg/dl)
- •Significant peripheral edema as per investigator's discretion
- •Known inability or unavailability of a patient to complete required study visits during study participation
- •A psychiatric condition (e.g., suicidal ideation) or chronic alcohol or drug abuse problem, determined from the patient's medical history, which, in the opinion of the investigator, may pose a threat to patient compliance
- •Use of a platelet-derived growth factor within 28 days before screening
- •Use of any investigational drug or therapy within 28 days before screening
- •Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study
研究组 & 干预措施
Granexin gel plus Standard of Care
Active Comparator
Granexin gel is comprised of 100 μM aCT1 peptide plus hydroxyethyl cellulose.
干预措施: Granexin gel (Drug)
Vehicle gel plus Standard of Care
Placebo Comparator
Vehicle gel is hydroxyethyl cellulose without active pharmaceutical ingredient.
干预措施: Vehicle gel (Other)
结局指标
主要结局
Incidence of complete wound closure at Week 12 based on investigator assessment
时间窗: Week 12
次要结局
- Time in days to first complete wound closure of the target ulcer based on investigator assessment over the 12 week treatment period(Week 12)
研究者
研究点 (29)
Loading locations...
相似试验
已完成
1 期
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg UlcersVenous Leg UlcerNCT02652572Xequel Bio, Inc.10
已完成
1 期
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot UlcersDiabetic Foot UlcersNCT02652754Xequel Bio, Inc.16
撤回
2 期
Study of the Efficacy and Safety of Granexin® Gel to Improve Burn Wound HealingSecond Degree BurnThermal BurnNCT04684121Xequel Bio, Inc.
已完成
3 期
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 StudyMigraineNCT02614196Eli Lilly and Company986
已完成
2 期
A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast SurgeryMammoplastyScarringBreast ReconstructionScarNCT04331080Xequel Bio, Inc.184